Last reviewed · How we verify
NCT07345052: WESST
Western Sweden Systemic Sclerosis Project
trial testing No Intervention: Observational Cohort in Scleroderma, Systemic in 150 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Sahlgrenska University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 20 June 2022 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- No Intervention: Observational Cohort — full drug profile →
Conditions studied
- Scleroderma, Systemic — all drugs for Scleroderma, Systemic →
- Fibrosis; Skin — all drugs for Fibrosis; Skin →
- Fibrosis Lung — all drugs for Fibrosis Lung →
- Interstitial Lung Disease Due to Systemic Disease — all drugs for Interstitial Lung Disease Due to Systemic Disease →
Sponsor
Sahlgrenska University Hospital
Who can join
18 and older, any sex, with Scleroderma, Systemic or Fibrosis; Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment options. A cohort of patients with SSc will be collected at the Sahlgrenska University Hospital in Gothenburg, Skaraborg Hospital in Skövde, and Södra Älvsborg Hospital in Borås (Sweden). Thanks to a holistic approach including integrated analysis of blood, and skin samples as well as DNA, and with the use of state-of-the-art methods, this project aims to identify factors (e.g. genes, proteins, metabolites, and immune cell types) associated with the development of SSc and with the progression to a more aggressive phenotype. Functional studies using in vitro model systems and patient specimens will be also implemented. The findings of the current project could lead to the identification of possible diagnostic and prognostic markers for the disease as well as potential drug targets. This cohort will be also linked to the European Scleroderma Trial and Research (EUSTAR), which is an international SSc research network aiming to coordinate research activities on SSc from groups all over Europe in order to improve treatment, quality of life and mortality of patients with SSc.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07345052
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention: Observational Cohort
Trials testing the same drug.
- NCT07284771 — MUSCLE-ML: Multimodal Integration of Muscle Strength, Structure by Machine Learning for Precision Rehabilitation After A · not yet recruiting
- NCT07414160 — Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients · not yet recruiting
- NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
- NCT07475468 — CP382 - Intermittent Catheter (IC) PRO Panel Plan · not yet recruiting
- NCT07382570 — Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months · not yet recruiting
Other recruiting trials for Scleroderma, Systemic
Currently open trials in the same condition.
- NCT06256575 — Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis · NA · recruiting
- NCT06697561 — Development and Evaluation of an Evidence-based Education Program for People With Hand Dysfunction in Scleroderma · NA · active not recruiting
- NCT05878717 — A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease · Phase 2, PHASE3 · recruiting
Other Sahlgrenska University Hospital trials
Trials by the same sponsor.
- NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
- NCT07524608 — Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Pa · not yet recruiting
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT06896578 — Latitude - Lateral Lymph Node Attitude Study · NA · not yet recruiting
- NCT07035600 — Walking and Sitting Difficulties After Rectal Cancer Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07345052 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sahlgrenska University Hospital
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07345052.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing